Overview
- Editors:
-
-
Robert B. Raffa
-
Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, USA
-
Ronald J. Tallarida
-
Department of Pharmacology, Temple University School of Medicine, Phhiladelphia, USA
- Provides background about the historical development of, and insight into, this condition
- Provides the ‘state-of-the-art’ of research (clinical and basic) and direction for future study
- More in-depth information is available from a variety of sources and so an extensive bibliography is provided
Access this book
Other ways to access
Table of contents (21 chapters)
-
-
-
- Robert B. Raffa, Kathleen J. Martin
Pages 11-12
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
- Christopher D. Aluise, Rukhsana Sultana, Jitbangjong Tangpong, Mary Vore, Daret St. Clair, Jeffrey A. Moscow et al.
Pages 147-156
About this book
Cancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. Due to the advances in chemotherapy and other aspects of prevention, early detection, and treatment modalities, an increasing percentage of patients are surviving the disease. For some types of cancer, the majority of patients live decades beyond their diagnosis. For this they are forever thankful and appreciative of the drugs that helped lead to this increased survival rate. But no drug is devoid of adverse effects. This also applies to chemotherapeutic agents. The acute cytotoxic effects of these agents are well known––indeed are often required for their therapeutic benefit. The chronic adverse effects are varied and in some cases less well known. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects.
Editors and Affiliations
-
Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, USA
Robert B. Raffa
-
Department of Pharmacology, Temple University School of Medicine, Phhiladelphia, USA
Ronald J. Tallarida
About the editors
ROBERT B. RAFFA, PhD, is Professor of Pharmacology and Chair of the
Department of Pharmaceutical Sciences at Temple University School of Pharmacy in Philadelphia, Pennslyvania. He holds B Chem E and BS degrees in Chemical Engineering and Physiological Psychology, MS degrees in Biomedical Engineering and Toxicology, and a PhD in Pharmacology. He is the co-author or editor of several books on pharmacology and thermodynamics and over 200 articles in refereed journals, and is active in NIH-funded research, editorial, and professional society activities. Dr. Raffa became co-founder and president of the Forget-Me-Not Foundation in 2009.
RONALD J. TALLAR IDA, PhD, is a Professor of Pharmacology at Temple
University School of Medicine. He has BS and MS degrees in physics/mathematics from Drexel University and a PhD in pharmacology. His work, primarily concerned with quantitative aspects of pharmacology, is represented in more than 250 published works that include eight books he has authored or co-authored. Dr. Tallarida currently
teaches, serves on editorial advisory boards, conducts NIH-funded research, and is active in professional societies. Dr. Tallarida became co-founder and Vice-president of the Forget-Me-Not Foundation in 2009.
